Suzhou, China, July 20, 2026—CStone Pharmaceuticals (“CStone,” HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that one of its core assets CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has been accepted for two Rapid Oral presentations at the European Society for Medical Oncology (ESMO) Congress 2026. The presentations will feature Phase I/II clinical data of CS2009 in patients with advanced non-small cell lung cancer (NSCLC) and patients with metastatic colorectal cancer (mCRC).

The abstract titles are now available on the official ESMO website. Please note that the data included in the submitted abstracts are as of April 2026, in accordance with the conference submission requirements. CStone will present more up-to-date clinical data with later cutoff dates at the ESMO Congress, to be held October 23–26, 2026 in Madrid, Spain.

Presentation details are as follows:

Presentation of CS2009 in Patients with Advanced Non-Small Cell Lung Cancer

【Title】: A phase 2 study of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer (NSCLC)

【Category】: NSCLC, metastatic

【Presentation Type】: Rapid Oral presentation

【Presentation Number】: 2616RO

【Date & Time】: Sunday, October 25, 2026, 08:30-10:00 a.m. CEST

Presentation of CS2009 in Patients with Metastatic Colorectal Cancer

【Title】: Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in metastatic colorectal cancer (mCRC): Results from a phase 1/2 study

【Category】: Investigational immunotherapy

【Presentation Type】: Rapid Oral presentation

【Presentation Number】: 1953RO

【Date & Time】: Saturday, October 24, 2026, 08:30-10:00 a.m. CEST

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 21 new drug applications covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit: www.cstonepharma.com.

IR contact: ir@cstonepharma.com

PR contact: pr@cstonepharma.com

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.